Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome

scientific article published on 11 December 2013

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2013-09-525915
P698PubMed publication ID24335103
P5875ResearchGate publication ID259320061

P2093author name stringMadeleine Duvic
Steven T Rosen
Joan Guitart
Youn H Kim
Stephen W Dusza
Christiane Querfeld
Timothy M Kuzel
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectphase II clinical trialQ42824440
mycosis fungoidesQ1891209
multicenter clinical trialQ6934595
P304page(s)1159-1166
P577publication date2013-12-11
P1433published inBloodQ885070
P1476titleResults of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome
P478volume123

Reverse relations

cites work (P2860)
Q48296904Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Q34516083Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents
Q36470196Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management
Q48034709Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
Q90070199Cutaneous lymphomas : Clinical presentation - diagnosis - treatment
Q49356636Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy.
Q98165138Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab
Q42087653Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
Q33430525Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study
Q64235061Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
Q90102093Mycosis fungoides: Developments in incidence, treatment, and survival
Q55334211New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
Q64883379Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
Q26774768Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas
Q26772207Primary cutaneous lymphomas: diagnosis and treatment
Q52962544Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide.
Q90485191Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases
Q88153215Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome
Q38229634Targeted therapies for cutaneous T-cell lymphomas
Q41573605The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
Q35071772c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death